Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole in Pediatric Bipolar Disorder
NCT00805493Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Nov 2008
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Riluzole with Placebo (2 arms). Primary endpoints: Clinical Global Impression - Improvement at 8 weeks and Pediatric Anxiety Rating Scale at 8 weeks. Started Nov 2008; status: terminated.
02
Drugs
riluzole
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00805493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805493.